Community pharmacist services for non‐hospitalised patients

Added May 13, 2020

Citation: de Barra M, Scott CL, Scott NW, et al. Pharmacist services for non‐hospitalised patients. Cochrane Database of Systematic Reviews 2018; (9): CD013102

What is this? The COVID-19 pandemic is placing a strain on healthcare services. Existing evidence on the effects of community pharmacies on patient care might provide useful information for policy makers.

In this Cochrane review, the authors searched for randomized trials that compared non-dispensing services provided by pharmacists in outpatient settings with usual or similar care provided by other healthcare professionals. They did not restrict their searches by date or language of publication and did their main search in March 2015, with an update search in January 2018. They included 116 trials (total 41,851 participants) from their 2015 search, with wide variability in the populations studied, the types of interventions delivered and reported outcomes. The authors identified a further 95 studies in 2018, which are awaiting classification.

What was found: Community pharmacist services may improve hypertension management and physical functioning compared to usual care; but, the effects for blood sugar control for patients with diabetes are uncertain.

Community pharmacist services probably make little or no difference to hospital admissions/attendance.

The effects of community pharmacist delivered interventions (compared to usual care) on adverse drug effects or mortality are uncertain.

The effects of community pharmacist delivered interventions (compared with services provided by other healthcare professionals) are uncertain.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.